Replies to post #2502 on Actinium Pharmaceuticals Inc (ATNM)

[timberwolf7]

any reason to reject the results of the PH 2 and or expect them to be any different in the PH 3?? Is 30% at 1 year, 20% at 2 years vs no survivors from the PH 2 at 2 years in the salvage arm?? Not to mention the shortened time to treatment thanks to the conditioning??
From my recall, the goal was to improve the results of not using it..

insert-text-here

In a Phase 2 clinical study in 58 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, Iomab-B produced complete remissions in 100% of patients and these patients experienced transplant engraftment at day 28. The overall survival rate of the 36 relapsed or refractory AML patients in the proof of concept study was 30% at one year and approximately 20% at two years. See Iomab-B study results here.

[Fosco1]

Okay,

As expected (and explained in previous post) we did not have an early termination for efficacy.

The good thing is that we did not have either early termination by the IDMC for lack of power. This was a possible outcome.

So the phase III trial will continue till 150 patients are recruited. This is the best possible outcome, the other and only one, as we explained in previous post, was for the trial to stop for futility in the control arm

The market does not like the news but the market was expecting something that could not happen.... what a shame and a waste of money : people just do not want to listen to things that don't please them ... In any case I would wait a little bit before buying back, the end of phase III is no way near with covid around
GL All
Fosco